Peptide library › Infections
Dalbavancin, oritavancin and telavancin
Also known as Dalvance, Orbactiv, Kimyrsa, Vibativ, Lipoglycopeptides
Long-acting hospital antibiotics related to vancomycin, used for serious skin infections including MRSA.
What people use it for
- Serious bacterial skin and skin-structure infections
- Hospital-acquired pneumonia (telavancin)
What Dalbavancin, oritavancin and telavancin does in the body
Glycopeptide antibiotics with a fatty tail. They block bacterial cell-wall building and, for some, damage the bacterial membrane. Dalbavancin and oritavancin last so long that one or two doses can replace days of treatment.
Strength of evidence
Strong: Phase 3 trials showed results similar to standard antibiotics.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Nausea and headache
- Infusion reactions
- Kidney problems and taste changes (telavancin)
- Interference with some blood-clotting tests (oritavancin, telavancin)
Who should avoid it or take extra care
- Pregnancy or breastfeeding, unless a specialist advises it (telavancin especially)
- Known allergy to glycopeptide antibiotics
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved: telavancin (2009), dalbavancin and oritavancin (2014). Hospital or clinic use.
How it's taken
Route: Drip into a vein; dalbavancin and oritavancin can be one or two doses
How long it lasts (half-life): Very long for dalbavancin (about 2 weeks) and oritavancin (about 10 days); about 8 hours for telavancin
Storage
Stored and prepared by the pharmacy or clinic, following the product label.
Latest research & news
- Oritavancin for CIED Infections With MDR Gram-positive Cocci
Clinical trial · Recruiting · Updated · ClinicalTrials.gov · 18 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Dalbavancin, oritavancin and telavancin privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Dalbavancin, oritavancin and telavancin in Fiala How to installMore in Infections
- BacitracinPeptide antibiotic in over-the-counter ointments for minor cuts and grazes.
- DaptomycinHospital antibiotic for serious skin and bloodstream infections, including MRSA.
- EchinocandinsFamily of hospital antifungal drugs for serious yeast and mould infections.
- Polymyxin B and colistinOld peptide antibiotics now kept as a last resort for multidrug-resistant gram-negative infections.
- VancomycinLong-established hospital antibiotic for MRSA and other serious infections; taken by mouth for C. difficile.
- EnfuvirtideFirst HIV fusion inhibitor, a twice-daily injection for resistant HIV; discontinued in the US in 2025.
- MurepavadinExperimental antibiotic designed to target Pseudomonas, the main lung infection in cystic fibrosis.
- BrilacidinExperimental drug that mimics the body's own antimicrobial defensins, studied for infections and inflammation.